Table 4.
Ledipasvir/sofosbuvir FDC for patients whose condition failed to respond to treatment with a protease inhibitor.
| Study | Population | Regimen | SVR12 PEG/RBV failures | SVR12 PI/PEG/RBV failures |
|---|---|---|---|---|
| ION-2 | GT1 TE (N = 440) | SOF/LDV, 12 weeks | 93% | 94% |
| (40/43) | (62/66) | |||
| SOF/LDV/RBV, 12 weeks | 96% | 97% | ||
| (45/47) | (62/64) | |||
| SOF/LDV, 24 weeks | 100% | 98% | ||
| (58/58) | (49/50) | |||
| SOF/LDV/RBV, 24 weeks | 98% | 100% | ||
| (58/59) | (51/51) |
FDC, fixed dose combination tablet; GT, genotype; LDV, ledipasvir; PEG, pegylated interferon; PI, protease inhibitor; RBV, ribavirin, SOF, sofosbuvir; TE, treatment experienced.